|
March 16, 2010
|
| 09:00 EDT |  | SIAL |
| theflyonthewall.com: | Sigma-Aldrich sees FY10 free cash flow grater than $350M | | This information is from a company slide presentation. :theflyonthewall.com |
|
| 08:58 EDT |  | SIAL |
|
| 08:57 EDT | | SIAL |
|
| 08:55 EDT | | SIAL |
| theflyonthewall.com: | Sigma-free cash flow improvement driven by $70M reduction in inventory | | This information is from a company slide presentation. :theflyonthewall.com |
|
| 08:53 EDT | | SIAL |
| theflyonthewall.com: | Sigma-Aldrich outlines five year financial targets | | In a company slides presentation Sigma-Aldrich gave its five year financial targets: Top line organic growth of 7%-8%; expand cumulative operating margins by 2014 to 200-300 bpts and achieve free cash flow of greater than $2B. :theflyonthewall.com |
|
| 07:09 EDT | | SIAL |
|
|
March 15, 2010
|
| 06:18 EDT | | SIAL |
| theflyonthewall.com: | Sigma-Aldrich agrees to sell Pfizer's bioactive small molecule compound | | Sigma-Aldrich (SIAL) announced that it has entered into an agreement with Pfizer (PFE) under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterization, assay development, screening and in vivo animal model applications. Under the agreement between the two companies, the Pfizer compounds, which include patented and approved drug molecules such as atorvastatin, sildenafil and celecoxib, will be made available to the research community while still on patent, in some cases for the first time. The inclusion of these Pfizer compounds provides authentic material that will help advance researchers' understanding of biological systems. :theflyonthewall.com |
|
|
March 11, 2010
|
| 16:31 EDT |  | SIAL |
| theflyonthewall.com: | Sigma-Aldrich to host conference call | | President and CEO Nagarkatti hosts a conference call to provide the company's annual business review on March 16 at 9:30 am. Webcast Link :theflyonthewall.com |
|
| 08:06 EDT | | SIAL |
|
Subscribe for More Information